HIM
CSCI

Hillsdale Investment Management’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Hillsdale Investment Management’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-631
Closed -$296K – 681
2019
Q1 		$296K Buy
631
+369
+141% +$143K 0.03% 376
2018
Q4 		$77K Buy
+262
New +$62.6K 0.01% 409

Other funds holding CSCI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hillsdale Investment Management's CSCI Position: Q2 2019 in Review

Hillsdale Investment Management sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q2 2019, closing a stake of 631 shares — an estimated $296K sold.

Hillsdale Investment Management first reported a position in CSCI in Q4 2018 and held it in 2 quarters. The position peaked at $296K in Q1 2019. 26 funds tracked by Wall St. Rank hold CSCI as of Q2 2019.

  • Hillsdale Investment Management reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Hillsdale Investment Management sold 631 COSCIENS Biopharma Inc. Common Stock shares in Q2 2019, an estimated $296K.
  • Hillsdale Investment Management first reported a position in COSCIENS Biopharma Inc. Common Stock in Q4 2018 and held it in 2 quarters.
  • Hillsdale Investment Management's COSCIENS Biopharma Inc. Common Stock position peaked at $296K in Q1 2019.
  • 26 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q2 2019.

Based on Hillsdale Investment Management's 13F filing for Q2 2019, filed 2 Aug 2019.